scholarly journals SARS-CoV-2 serologic immune response in exogenously immunosuppressed patients

2020 ◽  
Author(s):  
Megan L Zilla ◽  
Christian Keetch ◽  
Gretchen Mitchell ◽  
Jeffery McBreen ◽  
Michael R Shurin ◽  
...  
Keyword(s):  
Immune Response ◽  
Antibody Response ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Organ Transplant Recipient ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Immunosuppressed Patients ◽  
Solid Organ Transplant Recipients

Abstract Background While it is presumed that immunosuppressed patients, such as solid organ transplant recipients on immunosuppression, are at greater risk from SARS-CoV-2 infection than the general population, the antibody response to infection in this patient population has not been studied. Methods In this report, we follow the anti-SARS-CoV-2 antibody levels in patients with COVID-19 who are undergoing exogenous immunosuppression. Specifically, we studied the antibody response of three solid organ transplant recipient patients, three patients who take daily inhaled fluticasone, and a patient on etanercept and daily inhaled fluticasone, and compared them to five patients not on exogenous immunosuppression. Results We found that the solid organ transplant patients on full immunosuppression are at risk of having a delayed antibody response and poor outcome. We did not find evidence that inhaled steroids nor etanercept predispose patients to delayed immune response to SARS-CoV-2. Conclusion The data presented here suggest that solid organ transplant recipients may be good candidates for early targeted intervention against SARS-CoV-2.

scholarly journals Surgical-site mucormycosis infection in a solid-organ transplant recipient and a concise review of the literature

2019 ◽  
Vol 12 (12) ◽  
pp. e229687 ◽  
Author(s):  
Husham Haque ◽  
Scott Nettboy ◽  
Sunil Kumar
Keyword(s):  
Treatment Options ◽  
Organ Transplant ◽  
Alcoholic Cirrhosis ◽  
Solid Organ Transplant ◽  
Organ Transplant Recipient ◽  
Solid Organ Transplant Recipient ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

Surgical-site mucormycosis infections in solid-organ transplant recipients are rare conditions, with only 15 previously reported cases. We describe a case of a 49-year-old man who received a liver transplant due to alcoholic cirrhosis. On postoperative day 14, necrosis was noticed at the surgical site. After mucormycosis was diagnosed, monotherapy with amphotericin was started along with surgical debridements. Due to continued clinical deterioration, triple antifungal therapy was started with amphotericin, micafungin and posaconazole. Treatment with a granulocyte-macrophage colony-stimulating factor was also started. Despite therapy, the patient expired on postoperative day 31. We review the risk factors for mucormycosis infection in solid-organ transplant recipients as well as evidence for current treatment options. We also review the 15 previously reported cases of surgical-site mucormycosis infections in solid-organ transplant recipients, including time to infection, infecting organisms, mortality and treatments.

scholarly journals 156. Clinical Characteristics and Acute-phase Cytokine Response of Solid-Organ Transplant Recipients with Bloodstream Infections Differs According to Bacterial Type and Transplant Status

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S104-S104
Author(s):  
Emily Eichenberger ◽  
Felicia Ruffin ◽  
Sin-Ho Jung ◽  
Reginald Lerebours ◽  
Batu K Sharma-Kuinkel ◽  
...  
Keyword(s):  
Immune Response ◽  
Acute Phase ◽  
Clinical Characteristics ◽  
Organ Transplant ◽  
Host Immune Response ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

Abstract Background Clinical outcomes and host immune response in solid-organ transplant recipients (Tx) with Staphylococcus aureus bacteremia (SAB) and Gram-negative bacteremia (GNB) are poorly understood. The aims of this study were to describe (1) clinical characteristics and outcomes and (2) acute-phase cytokine response in Tx recipients with SAB and GNB as compared with matched non-transplant subjects (Non-Tx). Methods Thirty-two Tx recipients who were prospectively enrolled in the Blood Stream Infection Biorepository (BSIB) were matched 1:1 with Non-Tx patients on age, race, gender and bacteria using a perfect matching algorithm (Tx-SAB n = 16, Non-Tx SAB n = 16; Tx GNB n = 16, Non-Tx GNB n = 16). GNB included Escherichia coli (n = 16) and Klebsiella pneumoniae (n = 16). Multiplex cytokine testing was performed (Luminex) to evaluate acute-phase serum cytokines levels. Baseline characteristics were summarized using mean with standard deviation (SD), median with interquartile range (IQR), and ranges (min and max), or frequency with %. Differences between the Tx and Non-Tx SAB and GNB were compared using either the equal or unequal variance version of the Student’s t-test or Wilcoxon rank-sum test for continuous variables. Fisher’s exact test was used for categorical variables. Results An endovascular source was more common in Tx SAB vs. Non-Tx SAB (75.0% vs. 0.0%; P = 0.0003) and Tx-GNB (42.9% vs. 18.8%; P = 0.006). Fewer SAB cases were attributed to a skin/soft tissue/osteoarticular in Tx vs. Non-Tx (8.3% vs. 91.7%; P = 0.0001). APACHE II scores were higher in Tx SAB vs. Non-Tx SAB (14.0 [IQR: 11.0, 17.5] vs. 10.0 [IQR: 7.0, 12.5] P = 0.02), but not between Tx GNB vs. Non-Tx GNB (14 [IQR: 12.0, 15.5] vs. 13.5 [12.0, 15.0] P = 0.54). No significant difference length of stay, recurrent bacteremia or mortality were noted among or between groups. Patients with SAB had significantly higher levels of IL-10, CCL5, eotaxin vs. GNB in both Tx and Non-Tx. Conversely, IL-5, IL-13 and IL-17 levels were significantly lower in SAB compared with GNB in both Tx and Non-Tx. Within Tx alone, IL-8 and IL-15 were significantly higher in SAB as compared with GNB. Conclusion Significant differences exist in etiology and host immune response in Tx and Non-Tx with SAB and GNB. Further research is needed to understand the host immune response to BSI in these patients. Disclosures All authors: No reported disclosures.

scholarly journals Antibody Response to an mRNA SARS-CoV-2 Vaccine Following Initial Vaccination With Ad.26.COV2.S in Solid Organ Transplant Recipients

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Amy Chang ◽  
Jennifer L. Alejo ◽  
Aura T. Abedon ◽  
Jonathan Mitchell ◽  
Teresa P.-Y. Chiang ◽  
...  
Keyword(s):  
Antibody Response ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

scholarly journals Antibody Response to the Janssen COVID-19 Vaccine in Solid Organ Transplant Recipients

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Brian J. Boyarsky ◽  
Teresa P-Y Chiang ◽  
Michael T. Ou ◽  
William A. Werbel ◽  
Allan B. Massie ◽  
...  
Keyword(s):  
Antibody Response ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients

scholarly journals Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jennifer L. Alejo ◽  
Jonathan Mitchell ◽  
Teresa P.-Y. Chiang ◽  
Aura T. Abedon ◽  
Brian J. Boyarsky ◽  
...  
Keyword(s):  
Antibody Response ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Fourth Dose ◽  
Solid Organ Transplant Recipients

scholarly journals Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis

Vaccines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 95
Author(s):  
Orly Efros ◽  
Roi Anteby ◽  
Mirit Halfon ◽  
Eshcar Meisel ◽  
Eyal Klang ◽  
...  
Keyword(s):  
Antibody Response ◽  
Organ Transplant ◽  
Vaccine Dose ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Efficacy And Safety ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
The Third ◽  
Solid Organ Transplant Recipients

Solid organ transplant recipients were demonstrated to have reduced antibody response to the first and second doses of the COVID-19 mRNA vaccine. This review evaluated published data on the efficacy and safety of the third dose among solid organ transplant recipients. We performed a systematic search of PubMed, EMBASE, and Web of Science to retrieve studies evaluating the efficacy of the third dose of anti-SARS-CoV-2 vaccines in adult solid organ transplant recipients. Serologic response after the third vaccine was pooled using inverse variance and generalized linear mixed and random-effects models. Seven studies met our inclusion criteria. A total of 853 patients received the third dose. Except for one randomized controlled trial, all studies were retrospective in design. Following the third COVID-19 vaccine dose, antibody response occurred in 6.4–69.2% of patients. The pooled proportion of antibody response rate after the third vaccine was 50.3% (95% confidence interval (CI): 37.1–63.5, I2 = 90%). Five papers reported the safety profile. No severe adverse events were observed after the third vaccine dose. In conclusion, a third dose of the SARS-CoV-2 mRNA vaccine in solid organ transplant recipients is associated with improved immunogenicity and appears to be safe. Nevertheless, a significant portion of patients remain seronegative.

Antibody response of pediatric solid organ transplant recipients to immunization against influenza virus

1995 ◽  
Vol 127 (6) ◽  
pp. 957-960 ◽  
Author(s):  
Teri Jo Mauch ◽  
Norman A. Crouch ◽  
Deborah K. Freese ◽  
Elizabeth A. Braunlin ◽  
David L. Dunn ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Antibody Response ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Solid Organ Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document